Every 8-K that Medicinova (MNOV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MNOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNOV filings page.
MediciNova, Inc. (MNOV) has elected to terminate its Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville). The agreement, originally dated July 30, 2025, had allowed MediciNova, on a discretionary basis, to issue and sell up to $30.0 million of common stock to Yorkville. Under this facility, the company sold a total of 175,000 shares at prices between $1.39 and $1.40 per share, receiving aggregate proceeds of $0.2 million. The termination, made via a formal Notice of Termination dated August 31, 2026, will become effective on September 8, 2026. At termination, there were no outstanding borrowings, advance notices, or shares remaining to be issued under the agreement, and no fees are payable by either MediciNova or Yorkville in connection with ending the facility.
MediciNova, Inc. (MNOV) entered into new executive employment agreements with President & CEO Yuichi Iwaki and Chief Medical Officer Kazuko Matsuda, replacing their prior arrangements. The agreements set base salaries, bonus opportunities, and detailed severance protections tied to both ordinary terminations and Change in Control events.
Dr. Iwaki’s package includes a higher cash-and-equity severance multiple than in non‑Change in Control cases, while Dr. Matsuda’s agreement provides somewhat lower but similar protections. Both receive COBRA coverage for specified periods and 100% acceleration of unvested equity upon qualifying terminations in connection with a Change in Control. The agreements are at-will, governed by Delaware law, and include non‑solicitation, Section 280G cutback, and Section 409A compliance provisions.
MediciNova, Inc. reported results from its 2026 annual meeting of stockholders held on June 23, 2026. As of the April 24, 2026 record date, the company had 49,221,246 shares of common stock outstanding, and 29,774,819 shares were represented in person or by proxy, establishing a quorum.
Two director nominees, Hikedi Nagao and Nicole Lemerond, each received more votes "For" than "Against," with substantial broker non-votes recorded. Three additional proposals also showed more "For" than "Against" votes, based on totals of 26,697,794 vs. 1,911,245; 22,156,922 vs. 6,432,457; and 22,656,038 vs. 5,805,893, respectively.
MediciNova furnished preliminary, unaudited results for the year ended December 31, 2025 via its Tanshin report filed with the Tokyo Stock Exchange. Revenue was $0.41M, all from a Mayo Foundation ALS research agreement, versus no revenue in 2024.
The company recorded an operating loss of $13.28M and a net loss of $12.00M, slightly higher than 2024, as research and development held around $7.2M and general and administrative expenses rose to $6.16M including Standby Equity Purchase Agreement fees. Basic and diluted net loss per share was $0.24.
Cash and cash equivalents were $30.81M as of December 31, 2025, with operating cash outflow of $9.81M. MediciNova expects 2026 operating expenses of about $16.2M (an 18% increase) and believes current cash can fund operations at least through the end of February 2027, supported by existing ATM programs and a $30.0M standby equity facility.